On April 1, 2025, Inhibrx Biosciences appointed David J. Matly as President, increasing his salary to $601,670 and granting him 50,000 stock options, while Brendan P. Eckelman resigned as Chief Scientific Officer on March 31, 2025, with accelerated vesting of his options.